【摘要】 目的 分析卵巢癌患者中缺氧诱导因子-1α(Hypoxia inducible factor-1α,HIF-1α)的表达与贝伐单抗耐药的关系,研究HIF-1α对卵巢癌细胞的影响。方法 收集62例术后应用贝伐单抗治疗的卵巢癌患者的癌组织样本,并对HIF-1α进行免疫组化评估,分析HIF-1α与贝伐单抗耐药的关系。氯化钴诱导卵巢癌细胞SKOV3和ES-2后应用Realtime-PCR和Western blot分析HIF-1α和血管内皮生长因子(Vascular endothelial growth factor,VEGF)的表达情况。结果 HIF-1α在卵巢癌组织高表达,与患者的血清CA125(P=0.027)和贝伐单抗耐药(P<0.001)相关。低氧诱导SKOV3和ES-2卵巢癌细胞HIF-1α和VEGF表达明显增高。结论 卵巢癌中HIF-1α与贝伐单抗耐药相关,联合使用贝伐单抗和抗HIF-1α药物,可以增强化疗敏感性。更多还原

【Abstract】 Objective To investigate the relationship between HIF-1α and bevacizumab resistant in ovary cancer,and explore the influence on ovary cancer cell by HIF-1α.Methods The correlation was analyzed between HIF-1α expression and clinicopathological parameters using immunohistochemistry in 62 patients with ovarian cancer.In addition,the expression of HIF-1α and VEGF were evaluated by real time PCR or Western Blot in SKOV3 and ES-2 cell under CoCl 2 treatment.Results HIF-1α was overexpressed in cancer tissue,and its high levels were related to CA125(P = 0.027) and resistant to bevacizumab(P <0.001).Moreover,CoCl2 could induce high expressions of HIF-1α and VEGF,when compared to normal condition.Conclusion Our findings suggest that HIF-1α is associated with resistant to bevacizumab.It is more chemotherapeutic sensitivity when combined with bevacizumab and HIF-1α antibody.更多还原